HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 285/1/R84    most recent 00109.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Lee, S.-J. Articles by de Groat, W. C. Search for Related Content PubMed PubMed Citation Articles by Lee, S.-J. Articles by de Groat, W. C.

COMPLEX FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM, SLEEP AND LOCOMOTION

Effect of (±)-epibatidine, a nicotinic agonist, on the central pathways controlling voiding function in the rat

¹Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261; ²Department of Urology, Kyung Hee University College of Medicine, Seoul, Korea 130–702; and ³Department of Urology, Kanazawa University School of Medicine, Kanazawa, Ishikawa 920–8641, Japan

Submitted 6 March 2003 ; accepted in final form 4 April 2003

Nicotinic receptors in the brain modulate the release of many transmitters that are known to regulate voiding. This prompted us to examine the central nervous system effects of a neuronal nicotinic agonist, (±)-epibatidine, on voiding function in awake and anesthetized rats. Intracerebroventricular injection of (±)-epibatidine (0.1 µg) significantly increased intercontraction interval (ICI) but did not change pressure threshold (PT) or maximal voiding pressure (MVP), whereas 1 µg of (±)-epibatidine increased PT and MVP (P < 0.05) and decreased ICI. A low intravenous dose of (±)-epibatidine (0.001–0.1 µg) had no effect; however, a large dose of (±)-epibatidine (1 µg) significantly decreased ICI and increased MVP (P < 0.05) but did not change PT (P > 0.05). The effects occurred within 5–10 min after injection and persisted for 1–2 h. Intracerebroventricular chlorisondamine (10 µg), a nicotinic receptor antagonist, blocked the effect of intracerebroventricular (±)-epibatidine (0.1 µg). The experiments revealed that activation of nicotinic receptors in the brain increased bladder capacity in awake and anesthetized rats. These results suggest that the nicotinic agonist can activate mechanisms that inhibit voiding reflexes.

nicotinic acetylcholine receptors; central nervous system; chlorisondamine

This article has been cited by other articles:

				S.-F. Pan, H.-Y. Peng, C.-C. Chen, M.-J. Chen, S.-D. Lee, C.-L. Cheng, J.-C. Shyu, J.-M. Liao, G.-D. Chen, and T.-B. Lin Nicotine-activated descending facilitation on spinal NMDA-dependent reflex potentiation from pontine tegmentum in rats Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1195 - F1204. [Abstract] [Full Text] [PDF]

				J. M. Beckel, A. Kanai, S.-J. Lee, W. C. de Groat, and L. A. Birder Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells Am J Physiol Renal Physiol, January 1, 2006; 290(1): F103 - F110. [Abstract] [Full Text] [PDF]

				K.-E. Andersson and A. J. Wein Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence Pharmacol. Rev., December 1, 2004; 56(4): 581 - 631. [Abstract] [Full Text] [PDF]

				M. Gopalakrishnan and R. S. Bitner Neuronal nicotinic receptors: filling the void? Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R21 - R22. [Full Text] [PDF]